Perspective Therapeutics, Inc. (NYSE:CATX) CEO Purchases $117,000.00 in Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor bought 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 13th. The shares were purchased at an average cost of $1.17 per share, for a total transaction of $117,000.00. Following the completion of the transaction, the chief executive officer now owns 137,572 shares of the company’s stock, valued at $160,959.24. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Perspective Therapeutics Stock Performance

NYSE:CATX opened at $1.07 on Friday. Perspective Therapeutics, Inc. has a 1 year low of $0.21 and a 1 year high of $1.91. The company has a debt-to-equity ratio of 0.01, a current ratio of 12.98 and a quick ratio of 12.98.

Shares of Perspective Therapeutics are scheduled to reverse split before the market opens on Monday, June 17th. The 1-10 reverse split was announced on Monday, June 17th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, June 17th.

Perspective Therapeutics (NYSE:CATX) last posted its earnings results on Wednesday, May 15th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. Perspective Therapeutics had a negative net margin of 302.70% and a negative return on equity of 46.38%. The company had revenue of $0.33 million during the quarter. As a group, research analysts anticipate that Perspective Therapeutics, Inc. will post -0.11 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CATX. Janus Henderson Group PLC bought a new position in Perspective Therapeutics in the 1st quarter worth approximately $15,511,000. Affinity Asset Advisors LLC bought a new position in Perspective Therapeutics in the 1st quarter worth approximately $6,069,000. Vanguard Group Inc. raised its position in Perspective Therapeutics by 34.6% in the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after purchasing an additional 4,566,356 shares during the last quarter. HighTower Advisors LLC bought a new position in Perspective Therapeutics in the 3rd quarter worth approximately $314,000. Finally, Bank of New York Mellon Corp bought a new position in Perspective Therapeutics in the 3rd quarter worth approximately $42,000. Institutional investors own 54.66% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CATX. Cantor Fitzgerald began coverage on Perspective Therapeutics in a report on Thursday, May 9th. They set an “overweight” rating on the stock. B. Riley lifted their price objective on Perspective Therapeutics from $1.20 to $1.70 and gave the company a “buy” rating in a report on Tuesday, April 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $3.00 price objective on shares of Perspective Therapeutics in a report on Friday. Lifesci Capital reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a report on Monday, May 6th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $1.50 price objective (up from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $1.90.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.